Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ: MYGN) and its peers.
Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disorders, face strong tailwinds from advancements in precision medicine (including the use of AI to improve hit rates) and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug pricing, regulatory unknowns, and competition from larger, more resourced pharmaceutical companies could weigh on growth.
The 11 therapeutics stocks we track reported a very strong Q2. As a group, revenues beat analysts’ consensus estimates by 8%.
Luckily, therapeutics stocks have performed well with share prices up 19.4% on average since the latest earnings results.
Weakest Q2: Myriad Genetics (NASDAQ: MYGN)
Founded in 1991 as one of the pioneers in translating genetic discoveries into clinical applications, Myriad Genetics (NASDAQ: MYGN) develops genetic tests that assess disease risk, guide treatment decisions, and provide insights across oncology, women's health, and mental health.
Myriad Genetics reported revenues of $190.7 million, down 10.5% year on year. This print fell short of analysts’ expectations by 8.2%. Overall, it was a disappointing quarter for the company with full-year revenue guidance missing analysts’ expectations significantly and a significant miss of analysts’ EPS estimates.
“In the second quarter, we continued to make meaningful progress on the Cancer Care Continuum on a number of fronts, including 6% year-over-year volume growth supported by the ramp up of our expanded sales team, the launch of Prolaris + AI, the expansion of Precise MRD to include colorectal cancer (CRC) and renal cancers, along with the submission of Precise MRD breast to MolDX,” said Sam Raha, President and CEO, Myriad Genetics.
Myriad Genetics delivered the weakest performance against analyst estimates and weakest full-year guidance update of the whole group. The market seems disappointed with the results as the stock is down 40.8% since reporting and currently trades at $3.18.
Read our full report on Myriad Genetics here, it’s free.
Best Q2: Biogen (NASDAQ: BIIB)
Founded in 1978 and pioneering treatments for some of medicine's most complex challenges, Biogen (NASDAQ: BIIB) develops and markets therapies for neurological conditions, including multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, and rare diseases.
Biogen reported revenues of $2.74 billion, up 3.4% year on year, outperforming analysts’ expectations by 12.1%. The business had an incredible quarter with a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates.
The market seems happy with the results as the stock is up 7.5% since reporting. It currently trades at $220.99.
Is now the time to buy Biogen? Access our full analysis of the earnings results here, it’s free.
AbbVie (NYSE: ABBV)
Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE: ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.
AbbVie reported revenues of $16.99 billion, up 10.2% year on year, exceeding analysts’ expectations by 1.2%. Still, it was a mixed quarter as it posted a slight miss of analysts’ full-year EPS guidance estimates.
Interestingly, the stock is up 1.3% since the results and currently trades at $260.72.
Read our full analysis of AbbVie’s results here.
Vertex Pharmaceuticals (NASDAQ: VRTX)
Founded in 1989 with a mission to create medicines that treat the underlying causes of disease rather than just symptoms, Vertex Pharmaceuticals (NASDAQ: VRTX) develops and markets transformative medicines for serious diseases, with a focus on cystic fibrosis, sickle cell disease, and pain management.
Vertex Pharmaceuticals reported revenues of $3.33 billion, up 12.5% year on year. This print beat analysts’ expectations by 4.6%. Overall, it was a strong quarter as it also put up full-year revenue guidance slightly topping analysts’ expectations.
The stock is up 15.8% since reporting and currently trades at $545.
Read our full, actionable report on Vertex Pharmaceuticals here, it’s free.
United Therapeutics (NASDAQ: UTHR)
Founded by a mother seeking treatment for her daughter's pulmonary arterial hypertension, United Therapeutics (NASDAQ: UTHR) develops and commercializes medications for chronic lung diseases and other life-threatening conditions, with a focus on pulmonary hypertension treatments.
United Therapeutics reported revenues of $783.3 million, down 1.9% year on year. This number surpassed analysts’ expectations by 2.3%. It was a strong quarter as it also logged a beat of analysts’ EPS estimates.
The stock is down 6% since reporting and currently trades at $487.61.
Read our full, actionable report on United Therapeutics here, it’s free.
Market Update
Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership.
Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products.
By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals.
Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
